Myth #003: FDA BANNED PEPTIDES FOR SAFETY — Myth Buster

Following the money behind regulatory decisions

FDA BANNED PEPTIDES FOR SAFETY

WHAT PEOPLE SAY

The FDA removed peptides from compounding because they're dangerous and were harming people — it was a public health decision, plain and simple.

THE DATA

Each point of evidence assessed against the original claim.

No Safety Signal

FDA cited lack of data, not adverse events. No documented safety crisis triggered the removals.

Suspicious Timing

Ban finalized weeks before Eli Lilly's tirzepatide approval. Compounded versions cost 80-90% less.

Active Litigation

Outsourcing Facilities Association and compounding pharmacies have filed federal lawsuits challenging the decision.

Pharma Lobbying

Brand-name manufacturers spent $374 million lobbying Congress in 2023. Compounding pharmacies spent under $2 million.

Historical Pattern

Similar removals preceded other branded drug launches. Pattern suggests market clearing, not safety enforcement.

Some Valid Concerns

Compounding quality does vary. Sterility and dosing consistency are legitimate regulatory interests.

Data Gap Reality

Many peptides lack large-scale trials. Absence of safety data isn't proof of safety.

THE RULING

No safety crisis preceded the ban. Timing suggests market protection for newly-approved branded drugs, not consumer safety.

THE SCIENCE

ZERO DEATHS

No fatalities or serious adverse events from compounded peptides were cited in the FDA's removal justification.

$1,060 VS $50

Monthly cost of branded tirzepatide versus compounded versions. The price gap explains the lobbying intensity.

17 PEPTIDES

Number of compounds removed from the 503A bulk list in a single regulatory action — unprecedented scope.

FEDERAL LAWSUITS

Multiple legal challenges argue the FDA violated administrative procedure and acted arbitrarily.

WHY IT MATTERS

The FDA removed 17 peptides from the 503A bulking list in late 2023, citing insufficient safety data — not documented harm. This happened weeks before tirzepatide (Zepbound) hit the market at $1,060/month. Multiple lawsuits now challenge the decision, arguing the real motive was eliminating cheaper compounded competition.

REFERENCES

Feldman, R. & Frondorf, E. (2017). Drug Wars: How Big Pharma Raises Prices and Keeps Generics off the Market. Cambridge University Press.

Carrier, M.A. & Shadowen, S.D. (2016). Product Hopping: A New Framework. Notre Dame Law Review.

FDA Center for Drug Evaluation (2023). Bulk Drug Substances Used in Compounding Under Section 503A. Federal Register.

Outsourcing Facilities Association (2024). OFA v. FDA: Complaint for Declaratory and Injunctive Relief. U.S. District Court.

Wouters, O.J., Kanavos, P.G. & McKee, M. (2017). Comparing Generic Drug Markets in Europe and the United States. Milbank Quarterly.

Peptide Mythbuster. Evidence-based analysis.